Trial Profile
Investigator Sponsored Research Proposal : Efficacy and Safety of Combination Ambrisentan and TadaLafil in PATiEnts With PortoPulmonary Hypertension (ESCALATE-PPH)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary) ; Tadalafil (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms ESCALATE-PPH
- 05 Dec 2018 Planned End Date changed from 1 May 2019 to 1 Nov 2018.
- 05 Dec 2018 Planned primary completion date changed from 1 May 2019 to 1 Nov 2018.
- 05 Dec 2018 Planned initiation date changed from 1 Nov 2017 to 12 Oct 2017.